- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01075971
Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)
Evaluation of Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy
This is a multi-center, open-label, preference study of two sublingual formulations of buprenorphine HCl, in opioid-dependent patients on buprenorphine maintenance therapy.
The objectives of this study are to evaluate the overall preference between two buprenorphine sublingual formulations, after a switch from the marketed tablet (Subutex®) to the new fast dissolving tablet (FDT), in opioid-dependent patients with buprenorphine 8 mg or 16 mg daily maintenance therapy.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
- Patients must be at least (≥) 18 years of age, of either sex.
- Patients treated for opioid dependence with Subutex®, with a stable dosage of 8 mg or 16 mg daily, and respecting the legal drug attachments.
- Patients must understand and be able to adhere to the dosing and visit schedules, and agree to report concomitant medications / products and adverse events to the investigator or designee.
- Women of childbearing potential (includes women who are less than one year postmenopausal and women who become sexually active) must be using or agree to use an acceptable method of birth control (e.g., hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterile (e.g., hysterectomy or tubal ligation).
- Women of childbearing potential should be counseled in the appropriate use of birth control while in this study. Women who are not currently sexually active must agree and consent to use one of the above-mentioned methods should they become sexually active while participating in the study.
- Women of childbearing potential must have a urine pregnancy test with negative result within 2 weeks prior to inclusion (as performed under control of the investigator or designee).
Exclusion Criteria:
- Patients refusing to take the daily dose of the study medication under control in the center.
- Patients unable to complete the evaluations.
- Women who are pregnant or nursing.
- Patients with a history of hypersensitivity to buprenorphine hydrochloride or any excipient of one of its formulations.
- Patients with a current evidence of alcohol abuse.
- Patients with severe respiratory dysfunction, severe hepatic dysfunction, acute alcohol intoxication or delirium tremens.
Initiation or increase in the dose, within the past 7 days or scheduled during the study, of a treatment with:
- benzodiazepines,
- other depressants of the central nervous system: other morphine derivatives (analgesics, antitussives), certain antidepressive agents, sedative H1 antihistamines, barbiturates, benzodiazepines, anxiolytics other than benzodiazepines, neuroleptics, clonidine and clonidine-like agents,
- monoamine oxydase [MAO] inhibitors.
- Patients who have any current evidence of clinically significant hematopoietic, metabolic, cardiovascular, immunologic, neurologic, hematological, gastrointestinal, hepatic, renal, psychiatric, cerebrovascular, or respiratory disease, or any other disorder which, in the judgment of the investigator, may interfere with the study evaluations or affect patient safety.
- Patients who have used any investigational product within 30 days prior to enrollment.
- Patients participating in another trial at the same time.
- Patients intending to donate blood during the study or within 3 months after study completion.
- Patients in the exclusion period of the "Fichier National des personnes qui se prêtent à des recherches biomédicales sans bénéfice individuel direct" (National Index of persons participating in biomedical researches without direct individual benefit, or National Index of volunteers).
- Patients without Social Security number, or whose maximum annual compensation (3,800 €) has been exceeded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Buprenorphine hydrochloride
|
8 mg or 16 mg daily, sublingual route on Days 1 and 2
Other Names:
8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Overall Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine 8 mg or 16 mg Daily Maintenance Therapy.
Time Frame: Daily, Day 1 to Day 5
|
Patient's overall satisfaction on Day 1 to Day 5 postdose.
Marketed sublingual tablet (Marketed SL): Days 1 and 2; Fast dissolving tablet (FTD): Days 3, 4, and 5. Within 1 hour after complete dissolution of the tablet(s), overall satisfaction towards the study treatment was to be scored by the patient himself / herself using a 10-cm visual analogic scale (VAS) ranging from "Not at all satisfied" (score = 0) to "Totally satisfied" (score = 10).
|
Daily, Day 1 to Day 5
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P04451
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Dependency
-
Johns Hopkins UniversityCompletedOpioid Dependency
-
Mclean HospitalHarvard Medical School (HMS and HSDM)Completed
-
Indivior Inc.Completed
-
Titan PharmaceuticalsTerminated
-
Titan PharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedOpioid DependencyUnited States
-
University of California, Los AngelesCompleted
-
Weill Medical College of Cornell UniversityThe Institute for Family Health; New York State Health FoundationCompletedOpioid-Related Disorders | Opioid Use | Opioid Abuse | Prescription Drug Abuse and DependencyUnited States
-
Titan PharmaceuticalsCompleted
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedChronic Pain | Opioid DependencyUnited States
Clinical Trials on Buprenorphine hydrochloride marketed sublingual tablet (Subutex)
-
Psychiatric University Hospital, ZurichUnknownHeroin AddictionSwitzerland
-
T. John Winhusen, PhDNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingPregnancy Related | Opioid-Related Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Neonatal Abstinence Syndrome | Neonatal Opiate Withdrawal Syndrome | Drug Abuse in PregnancyUnited States
-
T. John Winhusen, PhDNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCActive, not recruitingPregnancy Related | Opioid-Related Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Neonatal Abstinence Syndrome | Drug Abuse in Pregnancy | Neonatal Opioid Withdrawal SyndromeUnited States
-
University of ChicagoCompleted
-
T. John Winhusen, PhDNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCActive, not recruitingPregnancy Related | Opioid-Related Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Neonatal Abstinence Syndrome | Drug Abuse in Pregnancy | Neonatal Opioid Withdrawal SyndromeUnited States
-
Indivior Inc.CompletedOpiate Dependence | Drug Dependence
-
Roxane LaboratoriesCompletedOpioid-Related DisordersUnited States
-
National Institute on Drug Abuse (NIDA)CompletedOpioid-Related DisordersUnited States
-
McNeil ABCompletedTobacco DependenceSweden
-
Wayne State UniversityCompletedEffects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence (BOS)Heroin Dependence | Opioid Use DisorderUnited States